Abstract. AREG (Amphiregulin), BTC (ß-cellulin), EGF, EPGN (Epigen), EREG (Epiregulin), HBEGF, NRG1, NRG2, NRG3, NRG4 and TGFA (TGF·) constitute EGF family ligands for ERBB family receptors. Cetuximab (Erbitux), Pertuzumab (Omnitarg) and Trastuzumab (Herceptin) are anticancer drugs targeted to EGF family ligands, while Gefitinib (Iressa), Erlotinib (Tarceva) and Lapatinib (GW572016) are anti-cancer drugs targeted to ERBB family receptors. AREG and TGFA are biomarkers for Gefitinib non-responders. The TCF/LEF binding sites within the promoter region of human EGF family members were searched for by using bioinformatics and human intelligence (Humint). Because three TCF/LEF-binding sites were identified within the 5'-promoter region of human AREG gene, comparative genomics analyses on AREG orthologs were further performed. The EPGN-EREG-AREG-BTC cluster at human chromosome 4q13.3 was linked to the PPBP-CXCL segmental duplicons. AREG was the paralog of HBEGF at human chromosome 5q31.2. Chimpanzee AREG gene, consisting of six exons, was located within NW_105918.1 genome sequence. Chimpanzee AREG was a type I transmembrane protein showing 98.0% and 71.4% total amino-acid identity with human AREG and mouse Areg, respectively. Three TCF/LEF-binding sites within human AREG promoter were conserved in chimpanzee AREG promoter, but not in rodent Areg promoters. Primate AREG promoters were significantly divergent from rodent Areg promoters. AREG mRNA was expressed in a variety of human tumors, such as colorectal cancer, liver cancer, gastric cancer, breast cancer, prostate cancer, esophageal cancer and myeloma. Because human AREG was characterized as potent target gene of WNT/ß-catenin signaling pathway, WNT signaling activation could lead to Gefitinib resistance through AREG upregulation. AREG is a target of systems medicine in the field of oncology.
Introduction
AREG (Amphiregulin), BTC (ß-cellulin), EGF, EPGN (Epigen), EREG (Epiregulin), HBEGF, NRG1, NRG2, NRG3, NRG4 and TGFA (TGF·) constitute EGF family ligands for ERBB family receptors (1, 2) . Ligand binding to ERBB receptors induces receptor dimerization, and the following autophosphorylation of tyrosine residues within the cytoplasmic region of receptors. SH2-or PTB-docking proteins are then recruited to the phosphotyrosine residues of ERBB receptors to activate the intracellular signaling cascades implicated in the regulation of a variety of cellular processes, such as growth, differentiation, apoptosis, adhesion and migration.
Cetuximab (Erbitux), Pertuzumab (Omnitarg) and Trastuzumab (Herceptin) are monoclonal antibodies targeted to EGF family ligands, while Gefitinib (Iressa), Erlotinib (Tarceva) and Lapatinib (GW572016) are small molecule inhibitors for ERBB family receptors (3) (4) (5) . Cetuximab, Pertuzumab, Trastuzumab, Gefitinib, Erlotinib and Lapatinib are anti-cancer drugs targeted to the ERBB signaling pathways. Upregulation of AREG or TGFA, functioning as ligands for ERBB family members, is associated with Gefitinib nonresponsiveness (6) .
Canonical WNT signaling pathway, transduced to the ß-catenin/TCF signaling cascade, plays a key role during embryogenesis, tissue regeneration and carcinogenesis (7) (8) (9) (10) (11) (12) (13) (14) ; however, WNT-dependent transcriptional regulation of EGF family members remains unclear. Here, TCF/LEF binding sites within the promoter region of human EGF family members were searched for. Because three TCF/LEF-binding sites were identified within the 5'-promoter region of human AREG gene, comparative genomics analyses on AREG orthologs were further performed.
Materials and methods
Screening of WNT target gene. Genome sequences corresponding to human AREG, BTC, EGF, EPGN, EREG, HBEGF, NRG1, NRG2, NRG3, NRG4 and TGFA genes were searched for with BLAST programs (http://www.ncbi.nlm. nih.gov) as described previously (15) (16) (17) (18) . TCF/LEF-binding sites within the 5'-flanking promoter region of the above genes were searched for based on bioinformatics and manual inspection as described previously (19) (20) (21) (22) .
Identification of chimpanzee AREG orthologs. Chimpanzee genome sequence homologous to human AREG was searched for with BLAST programs as described previously (23) (24) (25) (26) . Complete coding sequence (CDS) of chimpanzee AREG was determined by assembling exonic regions.
Comparative integromics analyses. Phylogenetic analyses on EGF family proteins as well as on promoters of mammalian AREG and HBEGF orthologs were performed by using the CLUSTALW program. Human and chimpanzee AREG promoters were then aligned by using Genetyx program and manual curation as described previously (27) (28) (29) (30) .
In silico expression analyses. Expressed sequence tags (ESTs) derived from human AREG gene were searched for by using the BLAST programs as described previously (31) (32) (33) (34) . The sources of human AREG ESTs were listed up for in silico expression analyses. (Fig. 1A) . TCF/LEF-binding sites within the 5'-promoter region of human EGF family genes were then searched for based on manual inspection. Three TCF/LEF-binding sites were identified within human AREG promoter (Fig. 1A) .
Results

Screening of TCF/LEF-binding
Comparative integromics analyses on AREG.
Comparative proteomics analysis was performed at first. Phylogenetic analysis on human and mouse EGF family members revealed that AREG and HBEGF are paralogs (Fig. 1B) . Intra-species comparative genomics analysis was next performed. PUMA, PFDN1, SLC4A9 and ANKHD1 genes were located around the HBEGF gene at human chromosome 5q31.2; however, paralogs of these genes were not located around the AREG gene (Fig. 1C) .
EPGN, EREG and BTC genes were directly linked to the AREG gene, which indicated the existence of EGF family gene cluster. PPBP, CXCL5, CXCL3, PPBPL2 and CXCL2 genes were located centromeric to the EPGN-EREG-AREG-BTC gene cluster. The EGF family gene cluster and the PPBP-CXCL segmental duplicons were closely linked at human chromosome 4q13.3 (Fig. 1C) .
Expression profile of human AREG. In silico expression analysis was performed to investigate the expression profile of human AREG mRNA. AREG mRNA was expressed in a variety of human tumors, such as colorectal cancer, liver cancer, gastric cancer, breast cancer, prostate cancer, esophageal cancer and myeloma.
Identification of chimpanzee AREG ortholog. BLAST programs using human AREG RefSeq revealed that chimpanzee AREG gene was located within NW_105918.1 genome sequence. Exon-intron boundaries of chimpanzee AREG gene were determined based on the consensus sequence of exon-intron junctions. Chimpanzee AREG gene was found consisting of six exons. Chimpanzee AREG complete CDS was determined by assembling exonic regions ( Fig. 2A) . Genetics program revealed that nucleotide position 211-969 was the coding region. Chimpanzee AREG gene was found to encode a 252-amino-acid AREG protein. Chimpanzee AREG was a type I transmembrane protein showing 98.0% and 71.4% total aminoacid identity with human AREG and mouse Areg, respectively (Fig. 2B) .
Comparative genomics analyses on AREG promoters. Human AREG promoter, chimpanzee AREG promoter, mouse Areg promoter and rat Areg promoter were located within AC021180.6, NW_105918.1, AC115067.7 and AC115469.4 genome sequences, respectively. Human HBEGF promoter, chimpanzee HBEGF promoter, mouse Hbegf promoter and rat Hbegf promoter were located within AC008438.6, NW_107080.1, AC147220.3 and AC097756.6 genome sequences, respectively. Phylogenetic analysis on the promoters of mammalian AREG and HBEGF orthologs revealed that primate AREG promoters were significantly divergent from rodent Areg promoters (Fig. 3A) .
Three TCF/LEF-binding sites within human AREG promoter were located about 1200, 600 and 300 bp upstream of the transcription start site (Fig. 3B) . Three TCF/LEFbinding sites within human AREG promoter were conserved in chimpanzee AREG promoter (Fig. 3B ), but not in rodent Areg promoters.
Discussion
TCF/LEF binding sites within the promoter region of human AREG, BTC, EGF, EPGN, EREG, HBEGF, NRG1, NRG2, NRG3, NRG4 and TGFA genes were searched for in this study. Because three TCF/LEF-binding sites were identified within the 5'-promoter region of the human AREG gene (Fig.  1A) , comparative genomics analyses on AREG orthologs were further performed.
Phylogenetics analyses revealed that AREG and HBEGF genes were paralogs within the human genome (Fig. 1B) . The EPGN-EREG-AREG-BTC cluster at human chromosome 4q13.3 was linked to the PPBP-CXCL segmental duplicons (Fig. 1B) . This fact indicates that human chromosome 4q13.3 was one of the hot spots for local duplications within the human genome.
Chimpanzee AREG gene, consisting of six exons, was found to encode a 252-amino-acid protein ( Fig. 2A) . Chimpanzee AREG was a type I transmembrane protein showing 98.0% and 71.4% total amino-acid identity with human AREG and mouse Areg, respectively. Phylogenetics analysis also indicated that AREG orthologs were relatively divergent compared with other EGF family orthologs. Together these facts indicate the protein evolution of AREG orthologs.
Three TCF/LEF-binding sites within human AREG promoter were conserved in chimpanzee AREG promoter, but not in rodent Areg promoters. Phylogenetic analysis also revealed that primate AREG promoters were significantly divergent from rodent Areg promoters. Together these facts indicate the promoter evolution of AREG orthologs.
In silico expression analysis in this study revealed that AREG mRNA was expressed in a variety of human tumors, such as colorectal cancer, liver cancer, gastric cancer, breast cancer, prostate cancer, esophageal cancer and myeloma. Kakiuchi et al reported that AREG upregulation is one of the biomarkers predicting Gefitinib non-responsiveness (6). Because human AREG was characterized as potent target gene of WNT/ß-catenin signaling pathway (Fig. 3B) , WNT signaling activation could lead to Gefitinib resistance through AREG upregulation. Therefore, AREG is a target of systems medicine, especially in the field of oncology.
